Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMelrose Regulatory News (MRO)

Share Price Information for Melrose (MRO)

Share Price is delayed by 15 minutes
Get Live Data
453.70    -5.90 (-1.28%)
Bid:
454.70
Ask:
454.90
Spread: 0.20 (0.044%)
Market Cap: £5.65b
MRO Live PriceLast checked at - London Stock Exchange

Intraday Melrose Share Chart

Financing Update

4 Aug 2020 07:00

RNS Number : 0505V
Melrose Industries PLC
04 August 2020
 

MELROSE INDUSTRIES PLC

 

4 August 2020

 

 

FINANCING UPDATE

 

Melrose Industries PLC ("Melrose" or the "Group") today issues an update on financing.

 

Following the trading updates on 30 March 2020 and 22 July 2020, Melrose has now agreed amended arrangements with its banking syndicate including improved financial covenants to 31 December 2022. Beyond that date the Group reverts to the original covenants for the balance of the facilities' term. These amendments cover all the Group's primary borrowing arrangements that contain financial covenants.

 

The Group's committed c.£3.2 billion revolving credit facility is repayable in January 2023 and the Group's committed term loan of c.£0.9 billion can be extended to April 2024 at Melrose's option. In addition to these committed banking lines the Group has two bonds: a £450 million bond maturing in September 2022 and a £300 million bond maturing in May 2032, neither of which contain financial covenants.

 

Melrose is grateful for the continued support of its lending banks which means that it has the flexibility it needs to continue to focus on cash generation and adapting the Group to current market conditions. The new financial covenants have been designed to give Melrose considerable headroom and flexibility.

 

There is a modest cash cost to secure this amendment but there is no change to previously agreed interest rate calculations. Melrose has passed its covenant tests for 30 June 2020 and would not in fact have needed the net debt: EBITDA waiver granted previously.

 

The improved financial covenants are shown in the table below:

 

Financial

Covenant

31 December 2020

30 June 2021

31 December 2021

30 June 2022

31 December 2022

Net debt :EBITDA

Waiver*

Waiver

5.25x**

4.75x**

4.0x**

EBITDA :Net finance charges

2.5x

3.0x

3.0x

3.25x

4.0x

*Announced on 30 March 2020

**Subject to downward adjustments upon certain material disposals

 

Following 31 December 2022, the financial covenants revert to 3.5x (for net debt: EDITDA) and remain at 4x (for EBITDA: net finance charges).

 

 

 

Simon Peckham, CEO of Melrose Industries PLC, said:

"We have now put in place new amended arrangements with our banks that last until the end of 2022. We thank our banks again for their continued support which gives us the headroom and flexibility to continue to focus on cash generation and adapt the Group as needed. Melrose also retains over £1 billion of cash liquidity. We are confident that we can position the Group to produce good returns for Shareholders."

- ends

 

Enquiries:

 

 

Montfort Communications:

Nick Miles

+44 (0) 20 3514 0897

+44 (0) 7973 130 669

miles@montfort.london

Charlotte McMullen

+44 (0) 20 3514 0897

+44 (0) 7921 881 800

mcmullen@montfort.london

Melrose Investor Relations:

+44 (0) 7974 974690

ir@melroseplc.net

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDEZLBBBVLXBBV
Date   Source Headline
23rd Aug 20185:07 pmRNSHolding(s) in Company
23rd Aug 20185:06 pmRNSHolding(s) in Company
22nd Aug 20187:00 amRNSNotice of Results
21st Aug 201811:59 amRNSHolding(s) in Company
20th Aug 20186:13 pmRNSHolding(s) in Company
16th Aug 20185:41 pmRNSHolding(s) in Company
10th Aug 20184:09 pmRNSHolding(s) in Company
8th Aug 20184:02 pmRNSVoting Rights and Capital
8th Aug 20181:39 pmRNSHolding(s) in Company
31st Jul 201811:49 amRNSHolding(s) in Company
30th Jul 20189:18 amRNSHolding(s) in Company
5th Jul 20182:25 pmRNSHolding(s) in Company
4th Jul 20184:59 pmRNSHolding(s) in Company
26th Jun 20181:05 pmRNSVoting Rights and Capital
26th Jun 201810:44 amRNSDirector/PDMR Shareholding
25th Jun 20187:00 amRNSCFIUS Clearance
8th Jun 201812:00 pmRNSPDMR Notification
31st May 20182:43 pmRNSVoting Rights and Capital
30th May 20186:04 pmRNSHolding(s) in Company
30th May 201811:36 amRNSHolding(s) in Company
25th May 20184:20 pmRNSDirector/PDMR Shareholding
24th May 20183:08 pmRNSVoting Rights and Capital
22nd May 20184:39 pmRNSHolding(s) in Company
22nd May 20184:34 pmRNSHolding(s) in Company
22nd May 20184:33 pmRNSHolding(s) in Company
22nd May 20184:32 pmRNSHolding(s) in Company
21st May 201810:56 amRNSHolding(s) in Company
21st May 20188:00 amRNSDelisting of GKN & Continuation Of Offer
18th May 20183:54 pmRNSHolding(s) in Company
17th May 20182:59 pmRNSVoting rights and capital
10th May 201812:01 pmRNSResult of AGM
10th May 20187:00 amRNSAGM Trading Update
9th May 20186:14 pmRNSHolding(s) in Company
8th May 20189:18 amRNSHolding(s) in Company
3rd May 20186:11 pmRNSHolding(s) in Company
2nd May 20187:00 amRNSHolding(s) in Company
1st May 20183:47 pmRNSVoting Rights and Capital
1st May 20182:20 pmRNSHolding(s) in Company
27th Apr 20187:00 amRNSCompulsory Acquisition of remaining GKN Shares
26th Apr 20186:03 pmRNSHolding(s) in Company
26th Apr 201810:17 amRNSHolding(s) in Company
25th Apr 20184:09 pmRNSHolding(s) in Company
25th Apr 201810:39 amRNSHolding(s) in Company
24th Apr 20183:19 pmRNSStatement re deeds of undertaking
24th Apr 20187:03 amRNSTRADING UPDATE FOR GKN PRIOR TO MELROSE OWNERSHIP
24th Apr 20187:00 amRNSHolding(s) in Company
24th Apr 20187:00 amRNSHolding(s) in Company
23rd Apr 20185:52 pmRNSHolding(s) in Company
23rd Apr 20185:50 pmRNSHolding(s) in Company
23rd Apr 20185:39 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.